secwatch.observer — SEC 8-K summary
======================================

Issuer:     Annovis Bio, Inc. (ANVS)
CIK:        0001477845
Form:       8-K
Filed at:   2026-10-30T21:10:31+00:00
Accession:  0001104659-26-120732
Event type: regulatory
Sentiment:  negative
Materiality: 0.70
Item codes: 3.01, 7.01, 9.01
LLM model:  deepseek-v4.1-flash:cloud@v2

Annovis Bio gets NYSE non-compliance notice; 30-day average market cap $48.4M, equity deficit $(4.3)M
--------------------------------------------------------------------------------

- NYSE notice dated Oct 29, 2026 cites Section 802.01B: 30 trading-day average market cap below $50M ($48.4M as of Oct 28) with stockholders' equity under $50M.
- Last reported stockholders' deficit was approximately $(4.3) million as of June 30, 2026, per the notice.
- Company will submit a cure plan within 45 days; NYSE has 45 days to accept, with a 9-month cure period from notice receipt.
- Ticker ANVS keeps trading but gains a ".BC" designation until compliance is regained; NYSE may act fast if shares trade below $0.10.
- Company says the notice does not affect operations, SEC reporting, or cause default under material debt agreements.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926120732/0001104659-26-120732-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1477845/000110465926120732/tm2628596d1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001104659-26-120732

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer